https://www.technologynetworks.com/drug-discovery/news/cti-completes-acquisition-of-pacritinib-a-highly-selective-jak2-inhibitor-191680
Phase 3 study in patients with myelofibrosis and low platelet counts targeted to start in Q4-2012.
cticompletesacquisitionpacritinibhighly